| | Journal of Acute Disease | |
|---|--------------------------|------------|
| Personality control for the role of the rol | Letter to Editor | |
| All A cale and any and a cale of a single + dropped in the single strategy and the single + dropped interview | | jadweb.org |
| a Vitine Gover Medicare | | |

doi: 10.4103/2221-6189.390392

Impact Factor® 0.5

A public health perspective on dengue in Bangladesh in the twenty-first century

Mehmet Uçar[™]

Department of Medical Services and Techniques, Varto Vocational School, Muş Alparslan University, Muş, Turkey

Infectious diseases have accompanied human history from time immemorial. In the 21st century, we have witnessed striking pandemics such as severe acute respiratory syndrome, middle east respiratory syndrome, malaria, and coronavirus disease 2019. Dengue fever is a mosquito-borne disease and is prevalent in tropical regions[1]. Female mosquito, such as *Aedes aegypti*, or *Aedes albopictus* to a lesser extent, is one major cause of infection with dengue virus (DENV)[2]. These mosquitoes serve as vectors not only for dengue but also for chikungunya, yellow fever, and Zika viruses. The infection could be attributed to four closely linked dengue viruses, each inducing a spectrum of symptoms. These symptoms demand medical intervention and hospitalization and sometimes are exceedingly mild or inconspicuous[1,2]. In severe instances, fatality can happen. Unfortunately, a remedy remains elusive.

Dengue fever is characterized as a self-limiting febrile ailment, presenting latent to severe symptoms. Manifestations of dengue fever typically emerge approximately 4-10 days after the bite of an infected mosquito^[3]. The common symptoms closely resemble those of influenza, including fever, cephalalgia, retroocular pain, myalgia, arthralgia, emesis, queasiness, rash, and profound fatigue^[2,3].

As the disease progresses, patients may experience respiratory distress, nasal and gingival bleeding, along with a swift deterioration leading to shock. In cases where symptoms are not alleviated after treatments, this progression can ultimately end in fatality[4]. Vigorous case management protocols for dengue fever within healthcare institutions have played a pivotal role in diminishing case fatality rates to below 1% in most heavily affected nations[5]. The yearly occurrence of dengue fever is estimated at approximately 100 million documented symptomatic cases, coupled with about 300 million asymptomatic infections[6]. Asia shoulders the greatest burden, accounting for 75% of reported cases, followed by Latin America and Africa[5,6]. From January 1st to November 14th, 2023,

the Bangladesh Ministry of Health and Family Welfare reported 295042 laboratory-confirmed cases of dengue fever and 1496 associated deaths, with a case fatality rate of 0.50%[7] (Table 1). Between January 1st and August 20th, 97860 cases and 476 deaths were recorded[6.7]. In comparison to the preceding five years, there has been a marked rise in case numbers and fatalities. DENV-2 (51.5%) constituted the predominant circulating serotype among 66 serotyped samples in June 2023[6.7].

Currently, dengue fever is endemic in Bangladesh and is a major concern of public health. The DENV can cause outbreaks with high morbidity and mortality. However, no targeted therapeutic regimen is currently available for afflicted cases, consequently, clinical management strategies for comprehensive supportive care are needed. Timely diagnosis and appropriate clinical interventions can decrease morbidity and mortality. The mitigation and control of dengue fever depends on the meticulous management of its vector population[6.7].

Owing to various social and economic factors, a substantial number of immigrants from Bangladesh to other nations and a significant influx of international tourists to Bangladesh heighten the risk of international disease transmission^[8]. Similar to the global

For reprints contact: reprints@medknow.com

©2023 Journal of Acute Disease Produced by Wolters Kluwer-Medknow.

How to cite this article: Uçar M. A public health perspective on dengue in Bangladesh in the twenty-first century. J Acute Dis 2023; 12(6): 255-256.

Article history: Received 25 September 2023; Revision 14 November 2023; Accepted 27 November 2023; Available online 12 December 2023

 $^{^{\}boxtimes}$ To whom correspondence may be addressed. E-mail: m.ucar@alparslan.edu.tr

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

| Year | Cases | Deaths | Case fatality rate |
|--------------------------|---------|--------|--------------------|
| 2018 | 10148 | 26 | 0.26% |
| 2019 | 101 354 | 164 | 0.16% |
| 2021 | 28429 | 105 | 0.37% |
| 2022 | 62382 | 281 | 0.45% |
| 2023 (as of 14 November) | 295042 | 1496 | 0.50% |

Table 1. Dengue cases, deaths, and case fatality rate in Bangladesh for 2018, 2019, 2021, 2022 and 2023.

Data source: Directorate General of Health Services, Ministry of Health & Family Welfare of Bangladesh (data for 2020 is limited due to COVID-19)[7].

spread of COVID-19, dengue fever could rapidly disseminate across borders[9]. Nations within the Asia Pacific region must remain vigilant against the threat of a dengue fever epidemic.

China's effective endeavors in malaria eradication^[10] can be adopted as a blueprint for overcoming Bangladesh's dengue crisis. China's approach revolves around targeting mosquito vectors, addressing the infection source, and protecting vulnerable individuals. Many effective steps should be taken such as the development of novel tools for early detection, management of *Aedes aegypti* and *Aedes albopictus*, fostering community awareness, and bolstering the healthcare system.

Conflict of interest statement

The authors report no conflict of interest.

Funding

This study received no extramural funding.

References

- [1] Wang C, Yang H, Xu J, Wang J, Zhao L, Hong W, et al. Association between serum albumin levels and disease severity in adult patients with dengue: A 7-year retrospective cohort study in mainland China. *Asian Pac J Trop Med* 2023; **16**(5): 204-212.
- [2] Rapp C. Dengue: une infection émergente [Dengue fever: an emerging infectious disease]. *Rev Prat* 2020; 70(3): 318-325 [in French].

- [3] Tayal A, Kabra SK, Lodha R. Management of dengue: An updated review. Indian J Pediatr 2023; 90(2): 168-177.
- [4] Kok BH, Lim HT, Lim CP, Lai NS, Leow CY, Leow CH. Dengue virus infection - A review of pathogenesis, vaccines, diagnosis and therapy. *Virus Res* 2023; **324**: 199018.
- [5] Lam SK. Challenges in reducing dengue burden; diagnostics, control measures and vaccines. *Expert Rev Vaccines* 2013; 12(9): 995-1010.
- [6] World Health Organization. Disease Outbreak News, Dengue -Bangladesh. [Online] Available from: https://www.who.int/emergencies/ disease-outbreak-news/item/2023-DON481 [Accessed on October 24, 2023].
- [7] Directorate General of Health Services, the Ministry of Health & Family Welfare of Bangladesh. Daily dengue status report. [Online] Available from: https://old.dghs.gov.bd/index.php/en/data [Accessed on November 14, 2023].
- [8] Hossain MS, Noman AA, Mamun SM, Mosabbir AA. Twenty-two years of dengue outbreaks in Bangladesh: Epidemiology, clinical spectrum, serotypes, and future disease risks. *Trop Med Health* 2023; **51**(1): 37.
- [9] Karakaya A, Uçar M. Stress perceptions of nurses serving in home healthcare services during the COVID-19 pandemic: A qualitative research. J Acute Dis 2023; 12(2): 73-79.
- [10]Wang D, Lv S, Ding W, Lu S, Zhang H, Kassegne K, et al. Could China's journey of malaria elimination extend to Africa? *Infect Dis Poverty* 2022; 11(1): 55.

Publisher's note

The Publisher of the *Journal* remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.